Question · asked by 1 review

Meloxicam vs naproxen: Participant‐reported pain relief of 50% or greater

Population
children and adolescents with chronic non‐cancer pain
Intervention
Meloxicam
Comparison
naproxen
Outcome
Participant‐reported pain relief of 50% or greater

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Meloxicam vs naproxen
Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane Headline outcomes only
no estimate extracted1 study · 225 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents
2017 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.